Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
deligoparin
- Development stage
- Phase 3
- Lead developer
- Opocrin
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Deligoparin (deligoparin sodium, code name OP 2000) is an ultra low molecular weight heparin developed as an anticoagulant and antithrombotic agent. It acts primarily as a Factor Xa inhibitor and also inhibits thrombin. Deligoparin was investigated for the treatment of ulcerative colitis and unstable angina pectoris but development was discontinued after reaching phase III clinical trials for ulcerative colitis in the US. The drug was originally developed by Opocrin[1][2]. As a member of the low molecular weight heparins class, it exerts its effect by potentiating antithrombin activity to inhibit clotting factors involved in thrombosis[1].
- Other names
- deligoparin sodiumOP 2000OP2000OP-2000
02
Targets
ATIII (Antithrombin III)F10 (Factor Xa)F2 (Thrombin)
Beyond the preview
Go deeper on deligoparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on deligoparin.